This morning at #AACR26 we invite you to join Senior Scientist Graham Garnett to learn about our new pan-RASi ADC platform, which integrates novel tricomplex pan-RAS inhibitors into ADCs to enable tumor-selective delivery and improved therapeutic index.

Graham's presentation